Dermata Therapeutics Inc (DRMA) Stock Price, Quote & News

Company Profile

Dermata Therapeutics, Inc., a late-stage medical dermatology company, focuses on identifying, developing, and commercializing pharmaceutical product candidates for the treatment of medical skin diseases and aesthetic applications. Its lead product candidate is XYNGARI, which is in Phase 3 clinical studies for the treatment of moderate-to-severe acne, as well as completed Phase 1b proof of concept (POC) trial for mild-to-moderate psoriasis. The company is also developing DMT410 that has completed...

Industry: Biotechnology

Sector: Healthcare

Phone: 858 800 2543

Website: www.dermatarx.com

Address:

3525 Del Mar Heights Rd., Suite 332, San Diego, United States

RoyalImperial Apr. 24 at 9:38 PM

MITQ looking ready, keep eyes on this one. Latest news + contracts rolling in Low float (~sub 10M) NO dilution Record earnings trend 📈. MITQ super undervalued-The entire company trades at 5.5M. It’s sitting on $3.9M in cash. That means you’re effectively buying the entire operating business $18M+ in annual revenue, proprietary products. $MODD $INAB $KEEL $DRMA $WW/...

1 · Reply

Aedea Apr. 24 at 1:34 PM

$DRMA worst bio ever

0 · Reply

Phazzatrades Apr. 23 at 9:07 PM

$DRMA

0 · Reply

Kesiya Apr. 23 at 8:47 PM

$CISS PT 111%-218%+ CISS Score/A FEE 60.36% Float :3.69M /Watchlist $ITOC $ZSPC $DRMA $IMCC

1 · Reply

HolEKa1010 Apr. 21 at 3:47 PM

$DRMA

0 · Reply

krakensos Apr. 21 at 8:53 AM

$DRMA Have they decided in the May 20th vote? Is it all in favor of the directors or all against?

0 · Reply

Guestthatrader Apr. 20 at 11:41 AM

$DRMA Galderma Galderma come Drma everybody knows released the news

0 · Reply

Guestthatrader Apr. 20 at 11:38 AM

$DRMA every time this stock showed movement before market open it runs it appears that this stock only moves on news

0 · Reply

BMWenjoyer Apr. 18 at 9:37 PM

$DRMA give some news

0 · Reply

brallt Apr. 17 at 2:39 PM

$DRMA That 1.40 down trend break on the daily is looking atractive. Gets fun at 2$+.

0 · Reply

Dermata Receives Notice of Acceptance of Australian Patent Application for Topical Application of Dermal Fillers with its Bioneedle Delivery System

Mar 26, 2026, 5:15 PM EDT - 4 weeks ago

Dermata Therapeutics Provides Corporate Update and Reports Financial Results for the Year Ended 2025

Mar 20, 2026, 10:39 AM EDT - 5 weeks ago

Dermata Shares Rise After USPTO Issues Patent Notice Of Allowance

Mar 10, 2026, 8:30 AM EDT - 6 weeks ago

Dermata Announces Appointment of Kyra Peckaitis as Vice President, Marketing

Mar 5, 2026, 9:00 AM EST - 7 weeks ago

Dermata Opens a New Chapter with the Release of Tome Skincare

Jan 20, 2026, 8:05 AM EST - 3 months ago

Dermata Receives Notice of Grant of Patent for Next-Generation Acne Treatment by Australian Patent Office

Dec 29, 2025, 4:05 PM EST - 4 months ago

Dermata Therapeutics Announces Closing of up to $12.4 Million Private Placement Priced At-The-Market Under Nasdaq Rules

Dec 24, 2025, 8:00 AM EST - 4 months ago

Dermata Therapeutics Announces up to $12.4 Million Private Placement Priced At-The-Market Under Nasdaq Rules

Dec 4, 2025, 8:00 AM EST - 5 months ago

A New Realm of Skincare is Coming: Dermata Teases New OTC Brand Identity

Nov 14, 2025, 4:05 PM EST - 5 months ago

Dermata Therapeutics Provides Corporate Update and Reports Third Quarter 2025 Financial Results

Oct 2, 2025, 8:00 AM EDT - 7 months ago

Dermata Announces Acceptance of Patent Application for Next-Generation Acne Treatment by Australian Patent Office

Sep 17, 2025, 1:00 AM EDT - 7 months ago

Dermata Therapeutics Announces Presentation of Abstract at the European Academy of Dermatology and Venereology Congress 2025

Sep 16, 2025, 8:35 AM EDT - 7 months ago

Dermata Therapeutics to Present at the Life Sciences Virtual Investor Forum September 18th

Sep 10, 2025, 8:00 AM EDT - 8 months ago

Dermata Therapeutics Announces Strategic Pivot to Over-the-Counter Skin Care Treatments

Aug 13, 2025, 5:00 PM EDT - 9 months ago

Dermata Therapeutics Provides Corporate Update and Reports Second Quarter 2025 Financial Results

Jul 8, 2025, 8:00 AM EDT - 10 months ago

Dermata Receives Notice of Grant of Australian Patent for Topical Botulinum Toxin Treatment for Hyperhidrosis

May 14, 2025, 9:00 AM EDT - 1 year ago

Dermata Therapeutics Provides Corporate Update and Reports First Quarter 2025 Financial Results

Apr 15, 2025, 8:30 AM EDT - 1 year ago

Dermata's XYNGARI(TM) Phase 3 Trial Hits Statistically Significant Difference at 4 Weeks

Mar 27, 2025, 8:15 PM EDT - 1 year ago

Dermata Therapeutics Announces Exercise of Warrants for $6.2 Million in Gross Proceeds Priced At-the-Market Under Nasdaq Rules

Mar 27, 2025, 10:21 AM EDT - 1 year ago

Nano-Cap Dermata Therapeutics Unveils Positive Data From Once Weekly Drug Study For Acne

Mar 27, 2025, 9:57 AM EDT - 1 year ago

Dermata Therapeutics Shares Surge on Positive Acne Treatment Study

Mar 27, 2025, 8:00 AM EDT - 1 year ago

BREAKING: Dermata's XYNGARI™ Phase 3 Trial Topline Data Meets All Primary Endpoints

Mar 17, 2025, 4:16 PM EDT - 1 year ago

Dermata Therapeutics Provides Corporate Update and Reports Year End 2024 Financial Results

Mar 4, 2025, 8:03 AM EST - 1 year ago

Dermata Announces that Last Patient Completes Last Visit in Pivotal XYNGARI™ Phase 3 STAR-1 Clinical Trial for Acne

Feb 25, 2025, 7:58 AM EST - 1 year ago

Dermata Receives Notice of Acceptance of Australian Patent Application for Topical Botulinum Toxin Treatment for Hyperhidrosis

Jan 29, 2025, 4:05 PM EST - 1 year ago

Dermata to Present on BioPub on January 31, 2025

Jan 28, 2025, 4:05 PM EST - 1 year ago

Dermata Expands Patent Portfolio with Issuance of New U.S. Patent for Next-Generation Acne Treatment

Jan 23, 2025, 4:15 PM EST - 1 year ago

Dermata Therapeutics Announces Closing of $2.55 Million Private Placement Priced At-The-Market Under Nasdaq Rules

Jan 22, 2025, 8:00 AM EST - 1 year ago

Dermata Therapeutics Announces $2.55 Million Private Placement Priced At-The-Market Under Nasdaq Rules

Jan 21, 2025, 8:00 AM EST - 1 year ago

Dermata and Revance Enter Clinical Trial Collaboration Agreement for the Topical Application of Xyngari(TM) with Daxxify(R)

Dec 16, 2024, 9:00 AM EST - 1 year ago

Dermata Receives Approval from FDA for the Proprietary Name Xyngari(TM)

Dec 10, 2024, 9:00 AM EST - 1 year ago

Dermata Receives Notice of Allowance for New U.S. Patent for DMT310 for the Treatment of Acne

Dec 3, 2024, 9:00 AM EST - 1 year ago

Dermata Completes Enrollment in First Pivotal DMT310 Phase 3 STAR-1 Clinical Trial for Acne

Nov 13, 2024, 4:15 PM EST - 1 year ago

Dermata Therapeutics Provides Corporate Update and Reports Third Quarter 2024 Financial Results

Nov 11, 2024, 8:35 AM EST - 1 year ago

Dermata Therapeutics to Present at the Life Sciences Investor Forum on Thursday, November 14, 2024

Oct 8, 2024, 4:15 PM EDT - 1 year ago

Dermata Therapeutics to Participate in the 2024 Maxim Healthcare Virtual Summit on Tuesday, October 15, 2024

Sep 17, 2024, 5:15 PM EDT - 1 year ago

Dermata Therapeutics Announces Closing of $3.5 Million Private Placement Priced At-The-Market Under Nasdaq Rules

Sep 16, 2024, 9:00 PM EDT - 1 year ago

Dermata Therapeutics Announces $3.5 Million Private Placement Priced At-The-Market Under Nasdaq Rules

Sep 5, 2024, 4:05 PM EDT - 1 year ago

Dermata Therapeutics Announces Participation at the H.C. Wainwright 26th Annual Global Investment Conference September 9-11, 2024

Aug 7, 2024, 4:05 PM EDT - 1 year ago

Dermata Therapeutics Provides Corporate Update and Reports Second Quarter 2024 Financial Results

Jul 17, 2024, 9:00 AM EDT - 1 year ago

Dermata Announces Achievement of 50% Enrollment in Pivotal DMT310 Phase 3 STAR-1 Clinical Trial for Acne

May 17, 2024, 8:30 AM EDT - 2 years ago

Dermata Therapeutics Announces Exercise of Warrants for $2.66 Million in Gross Proceeds Priced At-the-Market Under Nasdaq Rules

May 15, 2024, 4:05 PM EDT - 2 years ago

Dermata Therapeutics Provides Corporate Update and Reports First Quarter 2024 Financial Results

Mar 27, 2024, 4:05 PM EDT - 2 years ago

Dermata to Present at the Emerging Growth Conference on April 3, 2024

Mar 21, 2024, 4:05 PM EDT - 2 years ago

Dermata Therapeutics Provides Corporate Update and Reports Full Year 2023 Financial Results

Feb 1, 2024, 9:00 AM EST - 2 years ago

Dermata to Present at the Emerging Growth Conference on February 7, 2024

Jan 4, 2024, 4:05 PM EST - 2 years ago

Dermata Expands Global Intellectual Patent Portfolio with Issuance of Japanese Patent for DMT410 for the Treatment of Hyperhidrosis

Dec 20, 2023, 4:05 PM EST - 2 years ago

Dermata Enrolls First Patient in Pivotal DMT310 Phase 3 STAR-1 Clinical Trial for Acne

Nov 16, 2023, 1:30 PM EST - 2 years ago

Dermata Announces Exercise of Warrants for $2.26 Million in Gross Proceeds Priced At-the-Market Under Nasdaq Rules

Nov 16, 2023, 8:00 AM EST - 2 years ago

Dermata to Begin Enrolling Patients in DMT310 Phase 3 Acne Clinical Program in December 2023 based on Agreement with FDA on the Phase 3 Protocols

RoyalImperial Apr. 24 at 9:38 PM

1 · Reply

Aedea Apr. 24 at 1:34 PM

$DRMA worst bio ever

0 · Reply

Phazzatrades Apr. 23 at 9:07 PM

$DRMA

0 · Reply

Kesiya Apr. 23 at 8:47 PM

$CISS PT 111%-218%+ CISS Score/A FEE 60.36% Float :3.69M /Watchlist $ITOC $ZSPC $DRMA $IMCC

1 · Reply

HolEKa1010 Apr. 21 at 3:47 PM

$DRMA

0 · Reply

krakensos Apr. 21 at 8:53 AM

$DRMA Have they decided in the May 20th vote? Is it all in favor of the directors or all against?

0 · Reply

Guestthatrader Apr. 20 at 11:41 AM

$DRMA Galderma Galderma come Drma everybody knows released the news

0 · Reply

Guestthatrader Apr. 20 at 11:38 AM

$DRMA every time this stock showed movement before market open it runs it appears that this stock only moves on news

0 · Reply

BMWenjoyer Apr. 18 at 9:37 PM

$DRMA give some news

0 · Reply

brallt Apr. 17 at 2:39 PM

$DRMA That 1.40 down trend break on the daily is looking atractive. Gets fun at 2$+.

0 · Reply

SaltWaterChickens Apr. 16 at 7:14 PM

$DRMA our new sponsor - it placing the lotion on when its told or gets the hose again

0 · Reply

WildFireWarrior Apr. 16 at 2:04 PM

Make sure to keep eyes on ticker AMS ✅ About to go! This low float gem is starting to get found. Only 3M float, moves up very quick. Make sure to be earlyon AMS ✅ can be a big runner. $DRMA $VTAK $QVCGA $CAPS hot //.121

0 · Reply